Market Overview

Return On Capital Employed Overview: Cytokinetics


During Q2, Cytokinetics's (NASDAQ: CYTK) reported sales totaled $3.59 million. Despite a 6.57% in earnings, the company posted a loss of $32.36 million. Cytokinetics collected $3.83 million in revenue during Q1, but reported earnings showed a $30.36 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Cytokinetics posted an ROCE of 0.41%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Cytokinetics's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q2 Earnings Insight

Cytokinetics reported Q2 earnings per share at $-0.68/share, which did not meet analyst predictions of $-0.57/share.


Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: Earnings News